Literature DB >> 22906957

Hypertension and chronic kidney disease progression: why the suboptimal outcomes?

Anil K Bidani1, Karen A Griffin, Murray Epstein.   

Abstract

Current therapeutic interventions to retard the progression of chronic kidney disease have yielded disappointing outcomes despite adequate renin-angiotensin system blockade. The parameters to gauge the adequacy of blood pressure control need to be reassessed because clinic blood pressure constitutes a poor gauge of such control. The biologically relevant parameter for hypertensive target organ damage is total blood pressure burden, and reliance on isolated clinic blood pressure measurements per se does not accurately reflect the total blood pressure burden. This is particularly relevant to the population with chronic kidney disease in whom masked daytime or nocturnal hypertension and blood pressure lability are both widely prevalent and more difficult to control. Consequently, it is possible that the limited success currently being achieved in preventing or attenuating chronic kidney disease progression may be attributable in part to suboptimal 24-hour blood pressure control. Recent data and analyses also indicate that blood pressure variability, instability, episodic and nocturnal blood pressure elevations, and maximum systolic blood pressure may constitute additional strong predictors of the risk of target organ damage independently of mean systolic blood pressure. Accordingly, we suggest that future research should include the development of safe and effective strategies to achieve around-the-clock blood pressure control in addition to targeting mechanisms that reduce intrarenal blood pressure transmission or interrupt subsequent downstream pathways. Meanwhile, more aggressive use of patient education and home blood pressure monitoring with selection of longer-acting antihypertensive agents or nocturnal dosing should be considered to improve the current suboptimal results.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22906957      PMCID: PMC3943135          DOI: 10.1016/j.amjmed.2012.04.008

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  48 in total

Review 1.  Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers?

Authors:  H J Kloke; A J Branten; F T Huysmans; J F Wetzels
Journal:  Kidney Int       Date:  1998-06       Impact factor: 10.612

2.  Intensive blood-pressure control in hypertensive chronic kidney disease.

Authors:  Lawrence J Appel; Jackson T Wright; Tom Greene; Lawrence Y Agodoa; Brad C Astor; George L Bakris; William H Cleveland; Jeanne Charleston; Gabriel Contreras; Marquetta L Faulkner; Francis B Gabbai; Jennifer J Gassman; Lee A Hebert; Kenneth A Jamerson; Joel D Kopple; John W Kusek; James P Lash; Janice P Lea; Julia B Lewis; Michael S Lipkowitz; Shaul G Massry; Edgar R Miller; Keith Norris; Robert A Phillips; Velvie A Pogue; Otelio S Randall; Stephen G Rostand; Miroslaw J Smogorzewski; Robert D Toto; Xuelei Wang
Journal:  N Engl J Med       Date:  2010-09-02       Impact factor: 91.245

Review 3.  Renal fibrosis: novel insights into mechanisms and therapeutic targets.

Authors:  Peter Boor; Tammo Ostendorf; Jürgen Floege
Journal:  Nat Rev Nephrol       Date:  2010-09-14       Impact factor: 28.314

4.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

5.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

Review 6.  Pathophysiology of hypertensive renal damage: implications for therapy.

Authors:  Anil K Bidani; Karen A Griffin
Journal:  Hypertension       Date:  2004-09-27       Impact factor: 10.190

7.  Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.

Authors:  Lawrence J Appel; Jackson T Wright; Tom Greene; John W Kusek; Julia B Lewis; Xuelei Wang; Michael S Lipkowitz; Keith C Norris; George L Bakris; Mahboob Rahman; Gabriel Contreras; Stephen G Rostand; Joel D Kopple; Francis B Gabbai; Gerald I Schulman; Jennifer J Gassman; Jeanne Charleston; Lawrence Y Agodoa
Journal:  Arch Intern Med       Date:  2008-04-28

Review 8.  Ambulatory blood pressure and cardiovascular events in chronic kidney disease.

Authors:  Rajiv Agarwal
Journal:  Semin Nephrol       Date:  2007-09       Impact factor: 5.299

9.  The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.

Authors:  S Klahr; A S Levey; G J Beck; A W Caggiula; L Hunsicker; J W Kusek; G Striker
Journal:  N Engl J Med       Date:  1994-03-31       Impact factor: 91.245

10.  UK guidelines call for routine 24-hour ambulatory blood pressure monitoring in all patients to make the diagnosis of hypertension--not ready for prime time in the United States.

Authors:  Michael J Bloch; Jan N Basile
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-11-07       Impact factor: 3.738

View more
  11 in total

Review 1.  Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.

Authors:  Roland E Schmieder; Veselin Mitrovic; Christian Hengstenberg
Journal:  Clin Res Cardiol       Date:  2015-03-19       Impact factor: 5.460

Review 2.  Mechanisms of Synergistic Interactions of Diabetes and Hypertension in Chronic Kidney Disease: Role of Mitochondrial Dysfunction and ER Stress.

Authors:  Zhen Wang; Jussara M do Carmo; Alexandre A da Silva; Yiling Fu; John E Hall
Journal:  Curr Hypertens Rep       Date:  2020-02-03       Impact factor: 5.369

3.  BP Fluctuations and the Real-Time Dynamics of Renal Blood Flow Responses in Conscious Rats.

Authors:  Anil K Bidani; Aaron J Polichnowski; Hector Licea-Vargas; Jianrui Long; Stephanie Kliethermes; Geoffrey A Williamson; Karen A Griffin
Journal:  J Am Soc Nephrol       Date:  2019-12-02       Impact factor: 10.121

Review 4.  Renal microvascular dysfunction, hypertension and CKD progression.

Authors:  Anil K Bidani; Aaron J Polichnowski; Rodger Loutzenhiser; Karen A Griffin
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-01       Impact factor: 2.894

5.  Prognostic value of nighttime blood pressure load in Chinese patients with nondialysis chronic kidney disease.

Authors:  Yan Li; Qiongxia Deng; Huiqun Li; Xinxin Ma; Jun Zhang; Hui Peng; Cheng Wang; Tanqi Lou
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-05-07       Impact factor: 3.738

6.  Nocturnal Hypertension Correlates Better With Target Organ Damage in Patients With Chronic Kidney Disease than a Nondipping Pattern.

Authors:  Cheng Wang; Wen-Jie Deng; Wen-Yu Gong; Jun Zhang; Qun-Zi Zhang; Zeng Chun Ye; Tanqi Lou
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-06-04       Impact factor: 3.738

7.  The difference between nocturnal dipping status and morning blood pressure surge for target organ damage in patients with chronic kidney disease.

Authors:  Jun Song; Yongjie Li; Tong Han; Jianhao Wu; Tanqi Lou; Jun Zhang; Zengchun Ye; Hui Peng
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-11-08       Impact factor: 3.738

8.  Nighttime Systolic Blood-Pressure Load Is Correlated with Target-Organ Damage Independent of Ambulatory Blood-Pressure Level in Patients with Non-Diabetic Chronic Kidney Disease.

Authors:  Cheng Wang; Jun Zhang; Wenjie Deng; Wenyu Gong; Xun Liu; Zengchun Ye; Hui Peng; Tanqi Lou
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

9.  High prevalence of isolated nocturnal hypertension in Chinese patients with chronic kidney disease.

Authors:  Cheng Wang; Wen-Jie Deng; Wen-Yu Gong; Jun Zhang; Hua Tang; Hui Peng; Qun-Zi Zhang; Zeng-Chun Ye; Tanqi Lou
Journal:  J Am Heart Assoc       Date:  2015-06-18       Impact factor: 5.501

10.  Renoprotective effects of renin-angiotensin system inhibitor combined with calcium channel blocker or diuretic in hypertensive patients: A PRISMA-compliant meta-analysis.

Authors:  Yiming Cheng; Rongshuang Huang; Sehee Kim; Yuliang Zhao; Yi Li; Ping Fu
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.